Active
A Phase I study of a combination of the PARP inhibitor, Niraparib and Temozolomide or Irinotecan in patients with previously treated incurable Ewing Sarcoma
Type of Sarcoma:
Ewing Sarcoma
Drug:
Niraparib and Temozolomide or Irinotecan
Accrual Status:
Active
Overall Study Principal Investigator:
Sandra Strauss, MD, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute
Rashmi Chugh, MD
Assistant Professor
University of Michigan
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute
Rashmi Chugh, MD
Assistant Professor
University of Michigan
Co-Principal Investigators:
Sandra Strauss, MD, PhD
Senior Lecturer and Consultant Medical Oncologist
University College London, Cancer Institute
Rashmi Chugh, MD
Assistant Professor
University of Michigan